<DOC>
	<DOCNO>NCT00004795</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety efficacy synthetic dehydroepiandrosterone ( GL701 ) woman prednisone-dependent systemic lupus erythematosus . II . Describe pharmacokinetics GL701 .</brief_summary>
	<brief_title>Phase II/III Randomized , Double-Blind , Placebo-Controlled Study Dehydroepiandrosterone Women With Mild Moderate Systemic Lupus Erythematosus</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution . Patients randomly assign 1 2 dos oral dehydroepiandrosterone placebo , administer daily minimum 7 month . A prednisone taper attempt month patient stable improve disease . Therapy continue successful prednisone taper achieve sustain least 2 month , maximum 9 month . Patients follow 1 year entry .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Systemic lupus erythematosus American College Rheumatology criterion Mild moderate disease characterize follow : Prednisone dose ( equivalent ) 10 30 mg/day No daily dose 1 mg/kg great No alternateday regimen Failed prednisone taper last 12 month dose stable least 6 week prior entry OR No attempt taper last 12 month dose stable least 3 month prior entry No prior participation doubleblind dehydroepiandrosterone ( DHEA ) study Stanford University Prior/Concurrent Therapy No concurrent immunosuppressants No concurrent participation clinical study No investigational agent within long 30 day 10 half life agent At least 3 month since follow : Adrenocorticotropin hormone Androgens Cyclophosphamide Azathioprine Intravenous immune globulin Other immunosuppressant At least 1 month since change dose concurrent nonsteroidal anti inflammatory drug hydroxychloroquine Patient Characteristics No hypersensitivity DHEA inactive ingredient DHEA , i.e . : Cornstarch Lactose Magnesium stearate No condition would prevent adequate compliance study No history breast cancer reproductive tract malignancy Negative pregnancy test require within 2 week prior entry Reliable contraception require fertile woman No estrogencontaining oral contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic lupus erythematosus</keyword>
</DOC>